Negative in Ames, in vitro human lymphocyte micronucleus and in vivo mouse micronucleus assays
“Daraxonrasib was not mutagenic in the GLP in vitro Ames assay, not clastogenic in the GLP in vitro micronucleus assay with human peripheral blood lymphocytes, and not genotoxic in the GLP in vivo micronucleus study in mice.”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗
Carcinogenicity
Not conducted (advanced cancer indication, ICH S9)
“Carcinogenicity studies were not conducted with daraxonrasib, consistent with ICH S9 recommendations for advanced cancer indications.”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗
Reproductive & developmental
Mouse EFD: embryo-fetal toxicity at ≥50 mg/kg/day (2.5x clinical exposure by AUC)
“In an embryo-fetal development study in mice (25, 50, and 75 mg/kg/day), daraxonrasib caused embryo-fetal toxicity at ≥50 mg/kg/day (2.5x exposure at the recommended dose based on AUC).”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗
Safety pharmacology
Monkey CV study: decreased heart rate, prolonged QT, shortened QTc and increased blood pressure at all doses (3, 10, 30 mg/kg)
“In a standalone good laboratory practice (GLP) cardiovascular study in monkey, daraxonrasib demonstrated decreased heart rate, prolonged QT, shortened QTc (secondary to heart rate decrease), and increased blood pressure at all dose levels tested (3, 10, and 30 mg/kg).”
✓ VerifiedFDA multi-discipline review, p. 33Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative